Skip to main content
S

SCL Science Inc. — Investor Relations & Filings

Ticker · 246960 ISIN · KR7246960009 KO Professional, scientific and technical activities
Open in API
Filings indexed 309 across all filing types
Latest filing 2024-03-14 Proxy Solicitation & In…
Country KR South Korea
Listing KO 246960

About SCL Science Inc.

https://sclscience.com/en

SCL Science Inc., formerly InnoTherapy Inc., is a healthcare company focused on digital innovation and advanced medical technologies. The company develops and commercializes medical hemostatic agents based on its proprietary biomimetic technology, including the Bio-inspired Medical Materials (BiMM) product line. Leveraging 40 years of expertise in medical science, SCL Science is also dedicated to building a digital healthcare ecosystem using artificial intelligence and high-quality medical data. Its services extend to clinical trial analysis, bio-logistics, and an expanding drug discovery platform focused on AI-driven cancer vaccine development. The company serves hospitals, research laboratories, and other medical institutions.

Recent filings

Filing Released Lang Actions
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 1% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (Proxy Solicitation Statement) used to request shareholder votes for an upcoming Annual General Meeting (AGM). It contains meeting details, agenda items, and financial statements as required by law for proxy solicitation. This fits the 'Proxy Solicitation & Information Statement' category.
2024-03-14 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 1% confidence The document is a regulatory filing from a Korean company (InnoTherapy) announcing a significant change (over 30%) in revenue or profit structure compared to the previous fiscal year. This is a standard disclosure requirement for publicly traded companies in Korea (DART system) to inform investors of material financial shifts before the final audit is completed. It fits the definition of an Earnings Release (ER) as it provides key financial highlights and the primary reason for the change, rather than being a full annual report or a simple report publication announcement. FY 2023
2024-02-15 Korean
[기재정정]타법인주식및출자증권취득결정(자율공시)
M&A Activity Classification · 1% confidence The document is a regulatory filing from a Korean company (InnoTherapy) regarding the acquisition of shares in another company (H2U Corp.). It details the transaction, including the acquisition amount, purpose, and financial status of the target company. This type of disclosure, specifically regarding 'Acquisition of Shares and Securities of Other Corporations' (타법인주식및출자증권취득결정), is a standard corporate regulatory announcement in the Korean market. Since it does not fit into specific categories like M&A (which usually implies a takeover or merger) or capital changes (which usually refers to the company's own shares), it is best classified as a general regulatory filing.
2024-02-07 Korean
[기재정정]타법인주식및출자증권취득결정(자율공시)
M&A Activity Classification · 1% confidence The document is a regulatory filing from a Korean company (InnoTherapy) regarding the acquisition of shares in another company (H2U Corp). It is a formal 'Correction Report' (정정신고) for a previous disclosure regarding the acquisition of equity securities. This type of filing, which details corporate investment activities and regulatory disclosures, falls under the 'Regulatory Filings' category as it does not fit into specific categories like M&A (which usually implies full takeovers or mergers) or capital changes (which usually refers to the company's own shares).
2024-01-12 Korean
[기재정정]타법인주식및출자증권취득결정(자율공시)
M&A Activity Classification · 1% confidence The document is a regulatory filing from a Korean company (InnoTherapy) regarding the acquisition of shares in another company (H2U Corp.). It is a 'Correction Report' (정정신고) detailing changes to the acquisition date and investment details. This type of disclosure regarding corporate investment and M&A-related activity falls under the 'M&A Activity' (TAR) category in the provided schema, as it pertains to the acquisition of equity in another entity.
2023-12-28 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 1% confidence The document is a short regulatory announcement regarding the setting of a record date and shareholder register closure for the purpose of holding an Annual General Meeting. It does not contain the full report or proxy materials themselves, but rather serves as a formal notification of a corporate action. Given it is a standard regulatory disclosure regarding shareholder rights and meeting preparation, it fits best under the RNS (Regulatory Filings) category.
2023-12-13 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.